Translational Clinical Relevance of a Tomato-Derived Phytomelatonin Platform Produced by Combined Enzymatic Hydrolysis

Abstract

Background: Tomato fruit is a measurable dietary source of phytomelatonin, and tomato-derived extracts are increasingly being evaluated for sleep-related applications. Objective: We examined whether the analytical profile reported for the NVTIA tomato-derived phytomelatonin platform is consistent with the published human evidence base for melatonin and tomato-derived sleep interventions. Methods: We analyzed the process-performance dataset of the NVTIA platform and interpreted it in the context of peer-reviewed clinical and translational literature. Results: In the NVTIA dataset, the final melatonin content reached 98.2% to 99.1%, while total impurities were controlled within 1.0% to 1.5%. When rice-germ polyamines were omitted or the enzymatic hydrolysis conditions deviated from the pH and temperature window, melatonin content fell to 82.3% to 85.5% and impurities increased to 8.2% to 10.5%. Published food-chemistry data indicate that tomato fruits contain 7.5 to 250 ng/g dry-weight melatonin. In a meta-analysis of 17 controlled studies involving 284 participants, exogenous melatonin shortened sleep-onset latency by 4.0 min, improved sleep efficiency by 2.2%, and increased total sleep duration by 12.8 min. A double-blind randomized study of tomato extract in primary insomnia reported sleep-induction benefits over two weeks, and a more recent pilot study of tomato-derived phytomelatonin reported improvements in sleep latency, time awake, global PSQI score, and emotional well-being. Conclusion: The current evidence supports the clinical plausibility of a high-purity tomato-derived phytomelatonin ingredient and suggests that process quality is likely to matter for translational performance. Direct clinical superiority of NVTIA over other commercial ingredients, however, remains to be demonstrated in head-to-head randomized trials.